Portal de Periódicos da CAPES

Doxazosin for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Moderate Essential Hypertension: A Double-Blind, Placebo-Controlled, Dose-Response Multicenter Study

1995; Lippincott Williams & Wilkins; Volume: 154; Issue: 1 Linguagem: Inglês

10.1016/s0022-5347(01)67243-4

1527-3792

Jay Y. Gillenwater, Richard Conn, Steven G. Chrysant, Johnny Roy, Michael Gaffney, Kathleen Ice, Norma Dias,

Cardiovascular Syncope and Autonomic Disorders

No AccessJournal of UrologyClinical Urology: Original Article1 Jul 1995Doxazosin for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Moderate Essential Hypertension: A Double-Blind, Placebo-Controlled, Dose-Response Multicenter Study Jay Y. Gillenwater, Richard L. Conn, Steven G. Chrysant, Johnny Roy, Michael Gaffney, Kathleen Ice, and Norma Dias Jay Y. GillenwaterJay Y. Gillenwater , Richard L. ConnRichard L. Conn , Steven G. ChrysantSteven G. Chrysant , Johnny RoyJohnny Roy , Michael GaffneyMichael Gaffney , Kathleen IceKathleen Ice , and Norma DiasNorma Dias View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67243-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study. Doxazosin, a selective alpha 1-adrenoceptor antagonist, produced a significant increase in maximum urinary flow rate (2.3 to 3.6 ml. per second) at doses of 4 mg., 8 mg. and 12 mg., and in average flow rate (8 mg. and 12 mg.) compared with placebo. The increase in maximum flow rate was significant with doxazosin versus placebo within week of initiating double-blind therapy. Doxazosin compared to placebo significantly decreased patient-assessed total, obstructive and irritative BPH symptoms. Blood pressure was significantly lower with all doxazosin doses compared with placebo. Adverse events, primarily mild to moderate in severity, were reported in 48 percent of patients on doxazosin and 35 percent on placebo. Our results strongly support the use of doxazosin as a nonoperative therapeutic alternative in the management of uncomplicated BPH. Doxazosin would also be particularly useful in the management of patients who have BPH and hypertension. References 1 : Benign prostatic hyperplasia. In: . Philadelphia: W. B. Saunders Co.1992: 1009. chapt. 25. Google Scholar 2 : Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Brit. J. Urol.1975; 47: 193. Crossref, Medline, Google Scholar 3 : The capsule in benign prostatic hypertrophy. : Department of Health and Human Services, National Institutes of Health Publication No. 87-28811987: 221. Google Scholar 4 : Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol.1982; 128: 836. Link, Google Scholar 5 : Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol. Clin. N. Amer.1990; 17: 509. Google Scholar 6 : The use of alpha-adrenergic blockers in benign prostatic obstruction. Brit. J. Urol.1976; 48: 255. Medline, Google Scholar 7 : Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Brit. J. Urol.1987; 60: 136. Google Scholar 8 : A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol.1992; 148: 1467. Link, Google Scholar 9 : Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet1991; 337: 1457. Google Scholar 10 : alpha 1 Adrenoceptor subtypes in the human prostate. Brit. J. Urol.1994; 74: 585. Google Scholar 11 : Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Group. Eur. Urol.1993; 24: 319. Google Scholar 12 : Role of the sympathetic nervous system in hypertension and BPH. Brit. J. Clin. Pract.1994; 74: 13. Google Scholar 13 : Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in mild to moderate hypertension. Drugs1988; 35: 525. Google Scholar 14 : Pharmacokinetic overview of doxazosin. Amer. J. Cardiol.1987; 59: 78G. Google Scholar 15 : A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans. Amer. Ass. Genito-Urin. Surg.1977; 68: 29. Google Scholar 16 : The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate1992; 20: 89. Google Scholar 17 : A placebo-controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Brit. J. Urol.1978; 50: 551. Google Scholar 18 : Bladder outflow obstruction treated with phenoxybenzamine. Brit. J. Urol.1982; 54: 527. Google Scholar 19 : Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol.1993; 27: 39. Google Scholar 20 : A three-month double-blind study of doxazosin as treatment for benign prostatic outlet obstruction. Brit. J. Urol.1994; 74: 50. Google Scholar 21 : Efficacy and safety of doxazosin in hypertension therapy. Amer. J. Cardiol.1987; 59: 35G. Google Scholar 22 : A multicenter trial of doxazosin in West Germany. Amer. J. Cardiol.1987; 59: 40G. Google Scholar 23 : Effects of doxazosin on coronary heart disease risk factors in hypertension and BPH. Brit. J. Clin. Pract.1994; 74: 8. Google Scholar Departments of Urology, University of Virginia Medical School, Charlottesville, Virginia, Lovelace Scientific Resources Inc., Albuquerque, New Mexico, Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma, Oklahoma City, Oklahoma, and Pfizer Central Research, New York, New York.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKaplan S (2016) Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic HypertrophyJournal of Urology, VOL. 196, NO. 1, (192-193), Online publication date: 1-Jul-2016.ROEHRBORN C and SCHWINN D (2018) α1-Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic HyperplasiaJournal of Urology, VOL. 171, NO. 3, (1029-1035), Online publication date: 1-Mar-2004.KESTER R, MOOPPAN U, GOUSSE A, ALVER J, GINTAUTAS J, GULMI F, ABADIR A and KIM H (2018) Pharmacological Characterization of Isolated Human ProstateJournal of Urology, VOL. 170, NO. 3, (1032-1038), Online publication date: 1-Sep-2003.Yang S, Wang C, Hsieh C and Chen Y (2018) α1-Adrenergic Blockers in Young Men With Primary Bladder Neck ObstructionJournal of Urology, VOL. 168, NO. 2, (571-574), Online publication date: 1-Aug-2002.MARINKOVIC S and BADLANI G (2018) VOIDING AND SEXUAL DYSFUNCTION AFTER CEREBROVASCULAR ACCIDENTSJournal of Urology, VOL. 165, NO. 2, (359-370), Online publication date: 1-Feb-2001.MacDIARMID S, EMERY R, FERGUSON S, McGUIRT-FRANKLIN R, McINTYRE W and JOHNSON D (2018) A RANDOMIZED DOUBLE-BLIND STUDY ASSESSING 4 VERSUS 8 MG. DOXAZOSIN FOR BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 162, NO. 5, (1629-1632), Online publication date: 1-Nov-1999.CHON J, BORKOWSKI A, PARTIN A, ISAACS J, JACOBS S and KYPRIANOU N (2018) alpha1-ADRENOCEPTOR ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 161, NO. 6, (2002-2008), Online publication date: 1-Jun-1999.NARAYAN P and TEWARI A (2018) A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 160, NO. 5, (1701-1706), Online publication date: 1-Nov-1998.LEPOR H, WILLIFORD W, BARRY M, HAAKENSON C and JONES K (2018) THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSEJournal of Urology, VOL. 160, NO. 4, (1358-1367), Online publication date: 1-Oct-1998.MICHEL M, MEHLBURGER L, BRESSEL H, SCHUMACHER H, SCHAFERS R and GOEPEL M (2018) TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMS: DOES CO-MORBIDITY ALTER TOLERABILITY?Journal of Urology, VOL. 160, NO. 3 Part 1, (784-791), Online publication date: 1-Sep-1998.KYPRIANOU N, LITVAK J, BORKOWSKI A, ALEXANDER R and JACOBS S (2018) INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 159, NO. 6, (1810-1815), Online publication date: 1-Jun-1998.Lepor H, Kaplan S, Klimberg I, Mobley D, Fawzy A, Gaffney M, Ice K and Dias N (2018) Doxazosin for Benign Prostatic Hyperplasia: Long-term Efficacy and Safety in Hypertensive and Normotensive PatientsJournal of Urology, VOL. 157, NO. 2, (525-530), Online publication date: 1-Feb-1997. (2018) REPLY BY AUTHORSJournal of Urology, VOL. 154, NO. 1, (109-109), Online publication date: 1-Jul-1995. Volume 154 Issue 1 July 1995 Page: 110-115 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.Metrics Author Information Jay Y. Gillenwater More articles by this author Richard L. Conn More articles by this author Steven G. Chrysant More articles by this author Johnny Roy More articles by this author Michael Gaffney More articles by this author Kathleen Ice More articles by this author Norma Dias Multicenter Study Group: T. W. Ayres and J. W. Wescott, Daytona Beach, Florida; S. G. Chrysant and J. Roy, Oklahoma City, Oklahoma; A. T. K. Cockett, Rochester and S. A. Kaplan, New York, New York; R. L. Conn, Albuquerque, New Mexico; R. J. Correa, Seattle, Washington; A. Fawzy, New Orleans, Louisiana; S. D. Graham, Atlanta, Georgia; J. A. Heaney, Hanover, New Hampshire; J. L. Holtzman, Minneapolis and R. R. Moyer, Hibbing, Minnesota; J. S. Isen, Worcester and G. P. Lewis, New Bedford, Massachusetts; P. G. Katz, Richmond, Virginia; G. H. Malek, Madison, Wisconsin; and J. D. McConnell, Dallas and I. M. Thompson, Fort Sam Houston, Texas. More articles by this author Expand All Advertisement PDF downloadLoading ...